Adlai Nortye doses first patient in weekly-dosing arm of AN9025 Phase 1 trial

Adlai Nortye Ltd. (NASDAQ: ANL) announced on July 16, 2026 that the first patient has been dosed in the United States in the intermittent weekly dosing (QW) arm of the ongoing Phase 1 clinical trial of AN9025, a pan-RAS(ON) inhibitor.¹

Dr. Archie Tse, the company's President and Head of Research and Development, called the U.S. dosing event a significant step in evaluating AN9025 through a differentiated schedule, and said the company's preclinical data suggest that weekly dosing may allow for a wider therapeutic window, potentially supporting higher doses or better tolerability and combinability by giving normal tissue recovery time while still suppressing tumor RAS signaling.¹ He added that the company plans to share initial Phase 1 dose escalation data in 1H27 from the QD arm, with a potential early look at the QW arm.¹

The trial is described in the release as a first-in-human, open-label study across multiple centers, designed to assess safety, tolerability, pharmacokinetics, and anti-tumor effects of AN9025 in patients with advanced or metastatic solid tumors carrying RAS mutations.¹ It is being run as a multi-regional clinical trial conducted jointly with Jiangsu Aosaikang Pharmaceutical Co. Ltd. under a license agreement, with Adlai Nortye holding rights outside China and ASK Pharm holding rights in mainland China, Hong Kong, and Macao.¹ With this milestone, both the once-daily and once-weekly dose escalation arms are now enrolling patients.¹

According to the release, AN9025 is an oral small molecule designed to inhibit a broad range of RAS mutations, and preclinical work has shown it suppresses RAS-mutant cancers including pancreatic, lung, and colorectal tumors, with results the company describes as comparable to or better than an existing benchmark compound in its class.¹